Seer, Inc. will showcase proteomic insights at ASHG 2025, emphasizing its role in precision medicine and genomics research.
Quiver AI Summary
Seer, Inc., a leader in proteomics, will participate in the American Society of Human Genetics (ASHG) 2025 Annual Meeting from October 14-18 in Boston. The company aims to highlight the increasing significance of proteomics in complementing genomics for disease understanding and precision medicine. Seer will host a CoLab session focusing on multi-omic approaches in translational research and will have several presentations showcasing findings from independent research using the Proteograph® Product Suite. Topics include advancements from xenotransplantation studies and the identification of biomarkers in pulmonary fibrosis. CEO Omid Farokhzad emphasized the rapidly growing importance of proteomics in genetics research and its potential in precision medicine. Seer’s technology is designed to address the challenges faced by traditional proteomics, offering new insights and high-confidence results.
Potential Positives
- Seer is participating in a prominent conference (ASHG 2025 Annual Meeting), showcasing its leadership in the emerging field of proteomics and its integration with genomics.
- The company will host a featured CoLab session that highlights significant advancements in precision medicine, demonstrating the practical applications of its Proteograph Product Suite.
- Multiple independent research groups will present findings utilizing Seer’s technology, indicating growing adoption and trust in its platform within the global scientific community.
Potential Negatives
- Seer's products are stated to be for research use only, which could limit their market potential and accessibility for clinical diagnostic applications.
- The mention of "traditional proteomic technologies have struggled with inconsistent data, limited throughput, and prohibitive complexity" could imply that Seer's Proteograph may still face skepticism compared to established methods, which may affect adoption rates.
- While Seer's participation in a prestigious conference can be beneficial, it also places pressure on the company to deliver significant and market-changing results to justify their positioning in the industry.
FAQ
What is Seer's participation in the ASHG 2025 Annual Meeting?
Seer will host a CoLab session and participate in scientific presentations demonstrating its Proteograph Product Suite at the meeting.
When and where is the ASHG 2025 Annual Meeting being held?
The ASHG 2025 Annual Meeting takes place from October 14-18 in Boston.
What topics will be covered in Seer's CoLab session?
The session will explore multi-omic approaches in precision medicine, focusing on xenotransplantation and idiopathic pulmonary fibrosis.
How does Seer's technology enhance genomics research?
Seer’s Proteograph platform integrates proteomic data with genomic datasets for improved disease discovery and insight generation.
Who will present findings during Seer's scientific presentations?
Presenters include Joshua Bis and Claudia Langenberg, showcasing various insights from Seer's Proteograph platform across different research areas.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$SEER Insider Trading Activity
$SEER insiders have traded $SEER stock on the open market 5 times in the past 6 months. Of those trades, 0 have been purchases and 5 have been sales.
Here’s a breakdown of recent trading of $SEER stock by insiders over the last 6 months:
- OMID FAROKHZAD (CEO AND CHAIR) has made 0 purchases and 2 sales selling 67,655 shares for an estimated $139,337.
- DIPCHAND NISHAR sold 30,253 shares for an estimated $62,935
- DAVID R. HORN (PRESIDENT & CFO) has made 0 purchases and 2 sales selling 13,587 shares for an estimated $27,982.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$SEER Hedge Fund Activity
We have seen 32 institutional investors add shares of $SEER stock to their portfolio, and 29 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BLACKROCK, INC. removed 710,143 shares (-27.5%) from their portfolio in Q2 2025, for an estimated $1,519,706
- RENAISSANCE TECHNOLOGIES LLC added 291,704 shares (+35.3%) to their portfolio in Q2 2025, for an estimated $624,246
- CITADEL ADVISORS LLC added 210,062 shares (+510.2%) to their portfolio in Q2 2025, for an estimated $449,532
- ROYAL BANK OF CANADA added 192,195 shares (+261.2%) to their portfolio in Q2 2025, for an estimated $411,297
- MILLENNIUM MANAGEMENT LLC removed 167,434 shares (-32.9%) from their portfolio in Q2 2025, for an estimated $358,308
- GSA CAPITAL PARTNERS LLP added 119,701 shares (+177.7%) to their portfolio in Q2 2025, for an estimated $256,160
- HRT FINANCIAL LP added 119,507 shares (+inf%) to their portfolio in Q2 2025, for an estimated $255,744
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
REDWOOD CITY, Calif., Oct. 10, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced its participation at the upcoming American Society of Human Genetics (ASHG) 2025 Annual Meeting, taking place October 14-18 in Boston. As human genetics research increasingly moves from sequence to function, Seer’s presence at ASHG reflects how proteomics is becoming an essential complement to genomics in understanding disease biology and accelerating precision medicine. Seer will host a featured CoLab session and will be represented in multiple scientific presentations demonstrating how the Proteograph ® Product Suite enables researchers to translate genomic data into biological and clinical insight.
Seer CoLab Session
Advancing Precision Medicine Through Multi-Omics: Clinical Insights from Xenotransplantation and Fibrosis
Date/Time:
October 16, 2025 | 2:30-3:00 p.m. ET
Location:
Theater 1, Exhibit Hall
This featured session will highlight how multi-omic approaches powered by Seer’s Proteograph Product Suite are transforming translational genomics and clinical research.
-
Brendan Keating, PhD, Associate Professor, NYU Langone Health
, will present findings from gene-edited pig organ xenotransplants into humans, where integrated omics revealed immune and physiological dynamics critical for advancing compassionate use and first-in-human trials.
- Gloria Sheynkman, PhD, Assistant Professor, University of Virginia School of Medicine , will discuss how proteomic profiling identified isoform-specific biomarkers predicting survival differences in idiopathic pulmonary fibrosis, pointing to new avenues for targeted therapy in complex disease.
Together, these talks show how proteomics and genomics converge to uncover novel biomarkers, deepen understanding of disease mechanisms, and advance clinical translation.
Scientific Presentations Featuring Seer Technology
In addition to the CoLab session, several independent research groups will present findings generated using Seer’s Proteograph platform, reflecting its growing adoption across global academic and clinical institutions. These studies explore how Seer’s proteomic data can clarify and enhance prior findings from affinity-based methods and integrate with genomic datasets for disease discovery.
-
Triangulating orthogonal proteomic profiling methods to yield high-confidence protein targets
Presenter : Joshua Bis
Date/Time : October 16, 2025 | 12:00-1:00 p.m. | Poster 4063T
-
Proteogenomic prioritization of human knock-out mutations provides novel insights into function and clinical impact of genes across the genome and clinical specialties
Presenter : Claudia Langenberg
Date/Time : October 16, 2025 | 2:30-4:30 p.m. | Poster Session 4105T | Proteogenomics
“It’s remarkable to see how rapidly proteomics is rising in importance among genomics researchers, as reflected in the many exciting presentations at ASHG,” said Omid Farokhzad, Chair and CEO of Seer. “Proteins are the functional drivers of biology, and the proteome is extraordinarily complex. Empowering researchers to connect genetic variation to biological function through deep, unbiased proteomics at scale will help unlock the next phase of precision medicine. We’re thrilled to see so many researchers choosing Seer’s platform to help them make these connections and discoveries.”
About Seer, Inc.
Seer, Inc. (Nasdaq: SEER) sets the standard in deep, unbiased proteomics—delivering insights with scale, speed, precision, and reproducibility previously unattainable by other proteomic methods. Seer’s Proteograph Product Suite uniquely integrates proprietary engineered nanoparticles, streamlined automation instrumentation, optimized consumables, and advanced analytical software to solve challenges conventional methods have failed to overcome. Traditional proteomic technologies have struggled with inconsistent data, limited throughput, and prohibitive complexity, but Seer’s robust and scalable workflow consistently reveals biological insights that others do not. Seer’s products are for research use only and are not intended for diagnostic procedures. For more information about Seer’s differentiated approach and ongoing leadership in proteomics, visit www.seer.bio .
For more information, please visit booth #2586 or contact us at [email protected].
Media Contact:
Patrick Schmidt
[email protected]
Investor Contact:
Carrie Mendivil
[email protected]
